IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Montag & Caldwell LLC

Montag & Caldwell LLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 39.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 66,068 shares of the medical research company's stock after selling 43,518 shares during the quarter. IQVIA accounts for 2.7% of Montag & Caldwell LLC's holdings, making the stock its 20th biggest holding. Montag & Caldwell LLC's holdings in IQVIA were worth $15,287,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. International Assets Investment Management LLC acquired a new position in IQVIA during the 4th quarter worth approximately $13,759,000. Schwartz Investment Counsel Inc. grew its position in IQVIA by 4.1% during the 4th quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company's stock worth $41,345,000 after acquiring an additional 7,050 shares during the last quarter. Dfpg Investments LLC bought a new stake in IQVIA during the 4th quarter worth $1,106,000. Sei Investments Co. raised its position in IQVIA by 20.2% in the third quarter. Sei Investments Co. now owns 94,748 shares of the medical research company's stock valued at $18,641,000 after purchasing an additional 15,913 shares during the last quarter. Finally, Duality Advisers LP acquired a new stake in shares of IQVIA during the third quarter valued at about $491,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. SVB Leerink began coverage on shares of IQVIA in a report on Monday, February 26th. They set an "outperform" rating and a $290.00 target price on the stock. BTIG Research initiated coverage on IQVIA in a report on Tuesday, February 13th. They set a "buy" rating and a $285.00 target price on the stock. Guggenheim cut IQVIA from a "buy" rating to a "neutral" rating in a research note on Thursday, February 15th. UBS Group lifted their price objective on IQVIA from $240.00 to $300.00 and gave the stock a "buy" rating in a research note on Thursday, February 15th. Finally, Robert W. Baird increased their target price on shares of IQVIA from $226.00 to $251.00 and gave the company a "neutral" rating in a research report on Thursday, February 15th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $256.80.

Insider Activity

In related news, insider Ari Bousbib sold 31,678 shares of the company's stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company's stock, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now directly owns 20,836 shares of the company's stock, valued at approximately $5,031,894. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock worth $10,331,003 over the last ninety days. Company insiders own 1.60% of the company's stock.

IQVIA Stock Performance

Shares of IQVIA stock traded up $0.60 during trading hours on Monday, hitting $235.48. 740,092 shares of the company's stock traded hands, compared to its average volume of 967,241. The company has a fifty day simple moving average of $245.21 and a 200-day simple moving average of $223.56. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The stock has a market capitalization of $42.74 billion, a price-to-earnings ratio of 32.30, a PEG ratio of 2.27 and a beta of 1.50. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.82 by $0.02. The company had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm's quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the firm earned $2.54 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.